Compare · AXSM vs CAPR
AXSM vs CAPR
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Capricor Therapeutics Inc. (CAPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXSM and CAPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $12.68B, about 8.6x CAPR ($1.47B).
- Over the past year, AXSM is up 133.4% and CAPR is up 91.6% - AXSM leads by 41.8 points.
- AXSM has been more active in the news (23 items in the past 4 weeks vs 5 for CAPR).
- AXSM has more recent analyst coverage (25 ratings vs 9 for CAPR).
- Company
- Axsome Therapeutics Inc.
- Capricor Therapeutics Inc.
- Price
- $252.30+2.44%
- $25.10-0.89%
- Market cap
- $12.68B
- $1.47B
- 1M return
- +12.70%
- -20.17%
- 1Y return
- +133.45%
- +91.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 23
- 5
- Recent ratings
- 25
- 9
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Capricor Therapeutics Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Latest AXSM
- Director Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 units (SEC Form 4)
- Director Jeffs Roger converted options into 1,429 shares, increasing direct ownership by 2% to 58,939 units (SEC Form 4)
- Director Mahony Susan converted options into 1,429 shares and sold $145,017 worth of shares (600 units at $241.69) as part of a pre-agreed trading plan (SEC Form 4)
- Director Coleman Mark converted options into 1,429 shares and sold $160,107 worth of shares (643 units at $249.00) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 30,389 units (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Coleman Mark
Latest CAPR
- Capricor Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Capricor Therapeutics to Present at Upcoming Investor Conferences
- SEC Form 4 filed by CHIEF COMMERCIAL OFFICER Maurer Michael T
- SEC Form 3 filed by new insider Maurer Michael T
- CHIEF FINANCIAL OFFICER Bergmann Anthony exercised 3,000 shares at a strike of $1.39, increasing direct ownership by 36% to 11,223 units (SEC Form 4)
- Director Litvack Frank exercised 3,937 shares at a strike of $1.39, increasing direct ownership by 3% to 133,776 units (SEC Form 4)
- SEC Form 10-Q filed by Capricor Therapeutics Inc.
- Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Capricor Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits